Enhanced anti-metastatic bioactivity of an IGF-TRAP re-engineered to improve physicochemical properties.

ABSTRACT: The insulin-like growth factor (IGF) axis has been implicated in the progression of malignant disease and identified as a clinically important therapeutic target. Several IGF-1 receptor (IGF-1R) targeting drugs including humanized monoclonal antibodies have advanced to phase II/III clinical trials, but to date, have not progressed to clinical use, due, at least in part, to interference with insulin receptor signalling. We previously reported on the production of a soluble fusion protein consisting of the extracellular domain of human IGF-1R fused to the Fc portion of human IgG₁ (first generation IGF-TRAP) that bound human IGF-1 and IGF-2 with a 3 log higher affinity than insulin. We showed that the IGF-TRAP had potent anti-cancer activity in several pre-clinical models of aggres

SUBMITTER: Vaniotis G 

PROVIDER: S-EPMC6255772 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature